title: Expanding the scope of the "polypill" to heart failure.
authors.affiliation: Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA. mvaduganathan@partners.org
authors.forename: Muthiah
authors.initials: M
authors.lastname: Vaduganathan
authors.forename: Mihai
authors.initials: M
authors.lastname: Gheorghiade
authors.forename: Javed
authors.initials: J
authors.lastname: Butler
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000191:economics; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000737:chemistry / Q000191:economics; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000191:economics*; D002626:Chemistry, Pharmaceutical; D004338:Drug Combinations; D006333:Heart Failure / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000008:administration & dosage / Q000737:chemistry / Q000191:economics
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002316:Cardiotonic Agents; D004338:Drug Combinations; D000451:Mineralocorticoid Receptor Antagonists